International expert consensus on the role of hypersympathicotonia and the place of moxonidine in the treatment of arterial hypertension (2024) | Ukrainian Medical Journal

Osovska N.Yu.

Main
Publications
International expert consensus on the role of hypersympathicotonia and the place of moxonidine in the treatment of arterial hypertension (2024)

International expert consensus on the role of hypersympathicotonia and the place of moxonidine in the treatment of arterial hypertension (2024)

August 31, 2026

Cardiology, Rheumatology

Osovska N.Yu.

УДК: 616.12-008.331.1

Keywords :

arterial hypertension,

combination therapy,

hypersympathicotonia,

imidazoline receptors,

moxonidine,

sympathetic nervous system

Specialities :

Cardiology, Rheumatology

Resume

In 2024, the «Journal of Hypertension», the official publication of the International Society of Hypertension and the European Society of Hypertension, published an international expert consensus prepared by leading experts in arterial hypertension from Europe and Australia. Based on a structured review of the literature, 12 experts determined the place of moxonidine, a selective agonist of imidazoline I₁-receptors, in the modern treatment of arterial hypertension. The document supplements the current recommendations, highlighting in detail the role of increased sympathetic nervous system activity as a therapeutic target and justifying the use of moxonidine in patients with hypersympathicotonia. The article systematizes the key consensus statements, data on antihypertensive efficacy, metabolic effects and tolerability of the drug, and also proposes a practical algorithm for intensification of therapy in patients with uncontrolled arterial hypertension on the background of excessive sympathetic activation.

References

1. Schlaich M.P., Tsioufis K., Taddei S. et al. (2024) Targeting the sympathetic nervous system with the selective imidazoline receptor agonist moxonidine for the management of hypertension: an international position statement. J. Hypertens., 42(12): 2025–2040. DOI: 10.1097/HJH.0000000000003769.
2. Grassi G., Quarti-Trevano F., Cuspidi C. et al. (2025) Sympathetic overactivation in the resistant hypertensive phenotype: a meta-analysis of published studies. Hypertension, 82(8): 1346–1354. DOI: 10.1161/HYPERTENSIONAHA.125.24749.
3. Quarti-Trevano F., Seravalle G., Facchetti R. et al. (2025) Failure of antihypertensive treatment to restore normal sympathetic activity. Hypertension, 82(6): 1024–1034. DOI: 10.1161/HYPERTENSIONAHA.124.24429.
4. Érszegi A., Viola R., Bahar M.A. et al. (2024) Not first-line antihypertensive agents, but still effective — the efficacy and safety of imidazoline receptor agonists: a network meta-analysis. Pharmacology Research & Perspectives, 12(3): e1215. DOI: 10.1002/prp2.1215.
5. Cohn J.N., Pfeffer M.A., Rouleau J. et al. (2003) Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur. J. Heart Failure, 5(5): 659–667. DOI: 10.1016/S1388-9842(03)00163-6.
6. McEvoy J.W., McCarthy C.P., Bruno R.M. et al. (2024) 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. European Heart Journal, 45(38): 3912–4018. DOI: 10.1093/eurheartj/ehae178.
7. Faconti L., George J., Partridge S. et al. (2025) Investigation and management of resistant hypertension: British and Irish Hypertension Society position statement. J. Human Hypertens., 39: 1–14. DOI: 10.1038/s41371-024-00983-6.